

DAY 1 WEDNESDAY, 3 OCTOBER

14:00-14:10 Welcome and Introduction of Keynote Presenter

Boris Labar (Croatia)

14:10-15:00 Keynote Address:
State of the Art Therapy for CML
Hagop Kantarjian (USA)

SESSION 1: ACUTE LYMPHOCYTIC LEUKEMIAS

Moderators: Boris Labar, Farhad Ravandi

15:05-15:20 Prognostic implications of cytogenetic aberrations and molecular mutations in acute leukemia
Claudia Haferlach (Germany)

15:25-15:40 Significance of minimal residual disease in the acute leukemias
Invited

15:45-16:00 Impact of TKIs on Philadelphia chromosome+ ALL
Carlo Gambacorti-Passerini (Italy)

16:05-16:20 Therapeutic options for Philadelphia chromosome-like ALL
Yishai Ofran (Israel)

16:25-16:40 Treatment of Adolescents and Young Adults with ALL
Jean-Pierre Marie (France)

16:45-17:00 How should we treat older patients with ALL?
Max Topp (Germany)

17:05-17:20 BREAK

SESSION 2: ACUTE MYELOID LEUKEMIAS

Moderators: Boris Labar, Farhad Ravandi

17:20-17:35 Targeted therapy for AML using FLT3 and IDH1/2 inhibitors
Stephane de Botton (France)

17:40-17:55 Monoclonal antibodies and checkpoint inhibitors in AML
Farhad Ravandi (USA)

18:00-18:15 CPX351 and other novel therapies for AML
Richard Stone (USA)

18:20-18:35 CAR T cell therapy for acute leukemia
Partow Kebriaei (USA)

18:40-19:00 How will solving GVHD impact transplantation for acute leukemias?
Nikolas von Bubnoff (Germany)

19:00 Welcome Dinner/Reception

DAY 2 THURSDAY, 4 OCTOBER

7:30-9:00 Breakfast

SESSION 3: MYELOPROLIFERATIVE NEOPLASMS

Moderators: Lionel Ades, Srdan Verstovsek

9:05-9:20 Polycythemia Vera: Diagnosis and management
Francesco Passamonti (Italy)

9:25-9:40 Primer on atypical myeloproliferative neoplasms
Andreas Reiter (Germany)

9:45-10:00 What exactly is myelomonocytic leukemia? Differentiating CMML from everything else
Nadira Durakovic (Croatia)

10:05-10:20 JAK inhibitors for all classical Philadelphia negative MPN
Srdan Verstovsek (USA)

10:25-10:40 The MPN QOL International Study Group: Is quality of life a legitimate therapeutic target?
Claire Harrison (UK)

10:45-11:00 Stem cell transplantation for Philadelphia chromosome-negative MPNs in 2018
Matjaz Sever (Slovenia)

11:05-11:20 BREAK

SESSION 4: MYELODYSPLASTIC SYNDROMES

Moderators: Lionel Ades, Srdan Verstovsek

11:20-11:35 Microenvironment as therapeutic target in MPN/MDS
Rajko Kusec (Croatia)

11:40-11:55 Molecular determinants of MDS
Luca Malcovati (Italy)

12:00-12:15 Frontline therapy of low-risk MDS
Valeria Santini (Italy)

12:20-12:35 Frontline therapy of high-risk MDS
Uwe Platzbecker (Germany)

12:40-12:55 What novel new therapies may mean for the future of MDS
Lionel Adès (France)

13:00-13:20 When should transplant be offered as an option for MDS
Mateo Della Porta (Italy)

13:20-15:00 Lunch Symposium

Agenda is not final and subject to change
Speakers have been invited but not yet confirmed

SESSION 5: CHRONIC MYELOID LEUKEMIAS

Moderators: Hagop Kantarjian

- 15:00-15:15** Is minimal residual disease as significant in chronic leukemias as it is in acute leukemias?
Invited
- 15:20-15:35** Modulating the efficacy of tyrosine kinase inhibitors in CML
Jorge Cortes (USA)
- 15:40-15:55** Treating CML: In search of a balance
Michele Baccarani (Italy)
- 16:00-16:15** How quality of life issues impact choice of therapy for CML patients
Fabio Effiace (Italy)
- 16:20-16:35** BREAK

SESSION 6: CHRONIC LYMPHOCYTIC LEUKEMIAS

Moderators: Hagop Kantarjian

- 16:35-16:50** Molecular signature of CLL
Davide Rossi (Italy)
- 16:55-17:10** Frontline therapy in CLL
Claire Dearden (UK)
- 17:15-17:30** Therapy of older patients with CLL
Emili Montserrat (Spain)
- 17:35-17:50** Novel agents in CLL
William Wierda (USA)
- 17:55-18:15** Transplantation for CLL
Peter Dreger (Germany)

SESSION 7: ORAL POSTER PRESENTATIONS

- 18:15-19:00** TBA
- 19:00-20:00** Poster walk reception

DAY 3 FRIDAY, 5 OCTOBER

- 7:30-9:00** Breakfast

SESSION 7: B-CELL LYMPHOMAS

Moderators: Igor Aurer, Nathan Fowler

- 9:05-9:20** Overcoming anti-CD20 refractory disease in BCL with newer antibodies
Invited
- 9:25-9:40** Managing relapsed/refractory Hodgkin lymphoma
Anton Hagenbeek (The Netherlands)
- 9:45-10:00** Targeting the microenvironment in B-cell lymphoma
Nathan Fowler (USA)
- 10:05-10:20** Next generation approaches in primary CNS lymphoma
Invited

- 10:25-10:40** Looking beyond R-CHOP in diffuse large B-cell lymphoma
Marek Trnety (Czech Republic)
- 10:45-11:00** Moving beyond CHOP in mantle cell lymphoma
Invited
- 11:25-11:40** BREAK

SESSION 8: T-CELL LYMPHOMAS

Moderators: Madeleine Duvic, Ali Bazarbachi

- 11:45-12:00** Integrating immunotherapy into treatment paradigms for CTCL
Madeleine Duvic (USA)
- 12:05-12:20** Targeting the T-cell receptor pathway in peripheral T-cell lymphoma
Invited
- 12:25-12:40** Enhancing targeted therapies with epigenetic agents in PTCL
Owen O'Connor (USA)
- 12:45-13:05** Is there a role for stem cell transplantation in PTCL
Ali Bazarbachi (Lebanon)
- 13:05-14:35** Lunch Symposium

SESSION 9: MULTIPLE MYELOMA

Moderators: Dirk Hose

- 14:35-14:50** Prognostic factors in multiple myeloma
Nicollo Bolli (Italy)
- 14:55-15:10** Managing asymptomatic multiple myeloma
Dirk Hose (Germany)
- 15:15-15:30** Immunotherapy for multiple myeloma: Update on the IMIDS
Heather Landau (USA)
- 15:35-15:50** Maintenance therapy in multiple myeloma
Samo Zver (Slovenia)
- 15:55-16:10** Minimal residual disease in multiple myeloma
Toni Valkovic (Croatia)
- 16:15-16:35** New antibodies for multiple myeloma
Maria Gavriatopoulou (Greece)
- 16:35** Closing remarks

Agenda is not final and subject to change
Speakers have been invited but not yet confirmed